154 related articles for article (PubMed ID: 20976076)
1. Investigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells.
Afkhami F; Durocher Y; Prakash S
J Biomed Biotechnol; 2010; 2010():645610. PubMed ID: 20976076
[TBL] [Abstract][Full Text] [Related]
2. Microencapsulated mammalian cells for simultaneous production of VEGF165b and IFNα.
Afkhami F; Durocher Y; Prakash S
Artif Cells Blood Substit Immobil Biotechnol; 2012 Feb; 40(1-2):1-6. PubMed ID: 22288840
[TBL] [Abstract][Full Text] [Related]
3. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
4. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
[TBL] [Abstract][Full Text] [Related]
6. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy.
Joki T; Machluf M; Atala A; Zhu J; Seyfried NT; Dunn IF; Abe T; Carroll RS; Black PM
Nat Biotechnol; 2001 Jan; 19(1):35-9. PubMed ID: 11135549
[TBL] [Abstract][Full Text] [Related]
7. Rhaponticin decreases the metastatic and angiogenic abilities of cancer cells via suppression of the HIF‑1α pathway.
Kim A; Ma JY
Int J Oncol; 2018 Sep; 53(3):1160-1170. PubMed ID: 30015877
[TBL] [Abstract][Full Text] [Related]
8. Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs.
Benayoun L; Gingis-Velitski S; Voloshin T; Segal E; Segev R; Munster M; Bril R; Satchi-Fainaro R; Scherer SJ; Shaked Y
Stem Cells; 2012 Sep; 30(9):1831-41. PubMed ID: 22782858
[TBL] [Abstract][Full Text] [Related]
9. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
10. sFLT01: a novel fusion protein with antiangiogenic activity.
Bagley RG; Kurtzberg L; Weber W; Nguyen TH; Roth S; Krumbholz R; Yao M; Richards B; Zhang M; Pechan P; Schmid S; Scaria A; Kaplan J; Teicher BA
Mol Cancer Ther; 2011 Mar; 10(3):404-15. PubMed ID: 21252283
[TBL] [Abstract][Full Text] [Related]
11. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
[TBL] [Abstract][Full Text] [Related]
12. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
13. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
14. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
[TBL] [Abstract][Full Text] [Related]
15. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
17. VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.
Catena R; Larzabal L; Larrayoz M; Molina E; Hermida J; Agorreta J; Montes R; Pio R; Montuenga LM; Calvo A
Mol Cancer; 2010 Dec; 9():320. PubMed ID: 21194429
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
20. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo.
Tian F; Zhang X; Tong Y; Yi Y; Zhang S; Li L; Sun P; Lin L; Ding J
Cancer Biol Ther; 2005 Aug; 4(8):874-82. PubMed ID: 16082187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]